An isolation strategy for biomarkers that predict cancer relapse after 5-FU based adjuvant chemotherapy

被引：0
|
作者：
Nishizuka, Satoshi Stephen [1 ]
Ishida, Kazushige [2 ]
Uesugi, Noriyuki [1 ]
Chiba, Takehiro [1 ]
Matsuo, Teppei [1 ]
Yamada, Noriyuki [1 ]
Otsuka, Koki [1 ]
Koeda, Keisuke [1 ]
Sugai, Tamotsu [1 ]
Wakabayashi, Go [1 ]
机构：
[1] Iwate Med Univ, Sch Med, Morioka, Iwate 020, Japan
[2] NCI, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4129
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Physiologically Based Pharmacokinetic Modeling for Prediction of 5-FU Pharmacokinetics in Cancer Patients with Hepatic Impairment After 5-FU and Capecitabine Administration
    Wang, Yu
    Hu, Haihong
    Yu, Lushan
    Zeng, Su
    PHARMACEUTICAL RESEARCH, 2023, : 2177 - 2194
  • [42] LGR5 rs17109924 to predict chemoresistance to 5FU-based chemotherapy in adjuvant colon cancer.
    Gerger, Armin
    Herzog, Sereina
    Szkandera, Joanna
    Pichler, Martin
    Stotz, Michael
    Schaberl-Moser, Renate
    Samonigg, Hellmut
    Lax, Sigurd
    Leitner, Gerhard
    Renner, Wilfried
    Berghold, Andrea
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy
    Shebzukhov, YV
    Koroleva, EP
    Khlgatian, SV
    Lagarkova, MA
    Meshcheryakov, AA
    Lichinitser, MR
    Karbach, J
    Jager, E
    Kuprash, DV
    Nedospasov, SA
    IMMUNOLOGY LETTERS, 2005, 100 (01) : 88 - 93
  • [44] HOST ORGAN RECOVERY AND ANIMAL SURVIVAL AFTER CHEMOTHERAPY WITH 5-FU
    HOPKINS, HA
    LOONEY, WB
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 68 - 68
  • [45] Associations between epidermal growth factor receptor polymorphism and survival in colorectal cancer patients treated with 5-FU based adjuvant chemotherapy
    Lai, Ching-Yu
    Sung, Fung-Chang
    Hsieh, Ling-Ling
    Tang, Reiping
    Yeh, Chih-Ching
    CANCER RESEARCH, 2011, 71
  • [46] Neo-adjuvant chemotherapy with IV cisplatin and continuous infusion (CI) 5-FU versus IV cisplatin, CI 5-FU and vinorelbine in locoregionally advanced head and neck cancer
    Mantovani, G
    Bianchi, A
    Curreli, L
    Ghiani, M
    Massa, E
    Proto, E
    DelGiacco, GS
    10TH MEDITERRANEAN CONGRESS OF CHEMOTHERAPY, 1996, : 569 - 572
  • [47] BIOCHEMICAL MARKERS TO PREDICT RESPONSE OF LARGE BOWEL CANCER TO 5-FU
    MORGAN, LR
    POSEY, LE
    LEVIN, IA
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 211 - 211
  • [48] Beyond chemotherapy: Exploring 5-FU resistance and stemness in colorectal cancer
    Singh, Ursheeta
    Kokkanti, Rekha Rani
    Patnaik, Srinivas
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2025, 991
  • [49] ADJUVANT CHEMOTHERAPY WITH 5-FU AND BCNU IN CASES OF COLORECTAL ADENOCARCINOMAS AFTER XENOTRANSPLANTATION ON THYMUS DYSPLASTIC NUDE-MICE
    SCHMITZ, R
    PICHLMAYR, R
    NIKOLAIZIK, W
    LANGENBECKS ARCHIV FUR CHIRURGIE, 1981, : 247 - 251
  • [50] Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers
    Ishida, Kazushige
    Nishizuka, Satoshi S.
    Chiba, Takehiro
    Ikeda, Miyuki
    Kume, Kohei
    Endo, Fumitaka
    Katagiri, Hirokatsu
    Matsuo, Teppei
    Noda, Hironobu
    Iwaya, Takeshi
    Yamada, Noriyuki
    Fujiwara, Hisataka
    Takahashi, Masanori
    Itabashi, Tetsuya
    Uesugi, Noriyuki
    Maesawa, Chihaya
    Tamura, Gen
    Sugai, Tamotsu
    Otsuka, Koki
    Koeda, Keisuke
    Wakabayashi, Go
    PLOS ONE, 2012, 7 (08):
12345